Combination Therapy with Actos and Januvia

Critical Safety Considerations

The American College of Cardiology and other guideline societies imply that pioglitazone is absolutely contraindicated in all patients with established heart failure, regardless of NYHA functional class, due to fluid retention risk 1
For patients at high cardiovascular risk without established heart failure, the American Heart Association suggests using this combination with extreme caution, as sitagliptin provides some protection against heart failure development but does not eliminate pioglitazone's risk 1
Sitagliptin demonstrated cardiovascular safety with no increased heart failure risk in the TECOS trial, making it the preferred DPP-4 inhibitor for this combination, according to the American Diabetes Association 2

The American Association of Clinical Endocrinologists recommends weight and edema assessment at each visit during the first 3 months of combination therapy 1
The European Association for the Study of Diabetes suggests monitoring signs/symptoms of heart failure (dyspnea, orthopnea, peripheral edema) during the first 3 months of combination therapy 1
Renal function (eGFR) should be monitored every 3-6 months, according to the National Kidney Foundation 1
Liver enzymes should be monitored if using pioglitazone for MASH or if symptoms suggest hepatotoxicity, as recommended by the American Association for the Study of Liver Diseases 1

The American College of Cardiology recommends using lower pioglitazone doses (15 or 30 mg/day) rather than maximum doses to minimize fluid retention, weight gain, and fracture risk 1
Sitagliptin standard dose is 100 mg once daily for patients with normal renal function, according to the American Diabetes Association 2
For patients with renal impairment, the National Kidney Foundation suggests the following dose adjustments: eGFR ≥45 mL/min/1.73 m²: Sitagliptin 100 mg daily, eGFR 30-44 mL/min/1.73 m²: Sitagliptin 50 mg daily, eGFR <30 mL/min/1.73 m²: Sitagliptin 25 mg daily 2

The American Association of Clinical Endocrinologists suggests that the combination addresses both liver disease (pioglitazone improves steatohepatitis resolution) and cardiovascular risk (sitagliptin provides CV safety) in patients with MASH/NAFLD and type 2 diabetes 1
The National Kidney Foundation recommends that sitagliptin can be used down to eGFR <20 mL/min/1.73 m² with dose adjustment, while pioglitazone continues to provide glycemic control in patients with type 2 diabetes and CKD 1

The American Heart Association implies that any degree of established heart failure (NYHA Class I-IV) is a contraindication for this combination 1
The American Cancer Society suggests that a history of bladder cancer or active bladder cancer is a contraindication for this combination 1
The National Osteoporosis Foundation recommends that osteoporosis or high fracture risk, particularly in elderly women, is a contraindication for this combination 1
For patients with established atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease with albuminuria, the American Diabetes Association suggests prioritizing SGLT2 inhibitors or GLP-1 receptor agonists over this combination due to proven cardiovascular and renal benefits 4